Cancer immunotherapy by intratumoral injection of α-gal glycolipids

Giles F. Whalen, Mary Sullivan, Bilal Piperdi, Wahid Wasseff, Uri Galili

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim/Background: To determine the feasibility and safety of intratumoral α-gal glycolipids injection for conversion of human tumors into autologous Tumor Associated Antigens (TAA) vaccine. α-Gal glycolipids bind anti-Gal - the most abundant antibody in humans. Preclinical studies indicated that injected α-gal glycolipids insert into tumor cell membranes, bind anti-Gal and target tumor cells to Antigen Presenting Cells, thereby converting tumors into autologous TAA vaccines. We hypothesized that α-gal glycolipids might have similar utility in humans. Patients and Methods: Eleven patients with advanced solid tumors received one intratumoral injection of 0.1 mg, 1 mg, or 10 mg α-gal glycolipids. The primary endpoint was dose-limiting toxicity (DLT) within 4 weeks. Secondary endpoints included long-term toxicity, autoimmunity, radiological tumor response and survival. Results: There were no DLT and no clinical or laboratory evidence of autoimmunity, or any other toxicity. Few patients had an unexpectedly long survival. Conclusion: Intratumoral injection of α-gal glycolipids is feasible and safe for inducing a protective anti-tumor immune response.

Original languageEnglish (US)
Pages (from-to)3861-3868
Number of pages8
JournalAnticancer Research
Volume32
Issue number9
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

Glycolipids
Immunotherapy
Injections
Neoplasms
Autoantigens
Neoplasm Antigens
Autoimmunity
Vaccines
Survival
Antigen-Presenting Cells
Cell Membrane
Safety
Antibodies

Keywords

  • α-gal glycolipids
  • Anti-Gal antibody
  • Autologous tumor antigens
  • Cancer immunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Whalen, G. F., Sullivan, M., Piperdi, B., Wasseff, W., & Galili, U. (2012). Cancer immunotherapy by intratumoral injection of α-gal glycolipids. Anticancer Research, 32(9), 3861-3868.

Cancer immunotherapy by intratumoral injection of α-gal glycolipids. / Whalen, Giles F.; Sullivan, Mary; Piperdi, Bilal; Wasseff, Wahid; Galili, Uri.

In: Anticancer Research, Vol. 32, No. 9, 09.2012, p. 3861-3868.

Research output: Contribution to journalArticle

Whalen, GF, Sullivan, M, Piperdi, B, Wasseff, W & Galili, U 2012, 'Cancer immunotherapy by intratumoral injection of α-gal glycolipids', Anticancer Research, vol. 32, no. 9, pp. 3861-3868.
Whalen GF, Sullivan M, Piperdi B, Wasseff W, Galili U. Cancer immunotherapy by intratumoral injection of α-gal glycolipids. Anticancer Research. 2012 Sep;32(9):3861-3868.
Whalen, Giles F. ; Sullivan, Mary ; Piperdi, Bilal ; Wasseff, Wahid ; Galili, Uri. / Cancer immunotherapy by intratumoral injection of α-gal glycolipids. In: Anticancer Research. 2012 ; Vol. 32, No. 9. pp. 3861-3868.
@article{ea323bc1e76c4702806497ae5eb515f3,
title = "Cancer immunotherapy by intratumoral injection of α-gal glycolipids",
abstract = "Aim/Background: To determine the feasibility and safety of intratumoral α-gal glycolipids injection for conversion of human tumors into autologous Tumor Associated Antigens (TAA) vaccine. α-Gal glycolipids bind anti-Gal - the most abundant antibody in humans. Preclinical studies indicated that injected α-gal glycolipids insert into tumor cell membranes, bind anti-Gal and target tumor cells to Antigen Presenting Cells, thereby converting tumors into autologous TAA vaccines. We hypothesized that α-gal glycolipids might have similar utility in humans. Patients and Methods: Eleven patients with advanced solid tumors received one intratumoral injection of 0.1 mg, 1 mg, or 10 mg α-gal glycolipids. The primary endpoint was dose-limiting toxicity (DLT) within 4 weeks. Secondary endpoints included long-term toxicity, autoimmunity, radiological tumor response and survival. Results: There were no DLT and no clinical or laboratory evidence of autoimmunity, or any other toxicity. Few patients had an unexpectedly long survival. Conclusion: Intratumoral injection of α-gal glycolipids is feasible and safe for inducing a protective anti-tumor immune response.",
keywords = "α-gal glycolipids, Anti-Gal antibody, Autologous tumor antigens, Cancer immunotherapy",
author = "Whalen, {Giles F.} and Mary Sullivan and Bilal Piperdi and Wahid Wasseff and Uri Galili",
year = "2012",
month = "9",
language = "English (US)",
volume = "32",
pages = "3861--3868",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Cancer immunotherapy by intratumoral injection of α-gal glycolipids

AU - Whalen, Giles F.

AU - Sullivan, Mary

AU - Piperdi, Bilal

AU - Wasseff, Wahid

AU - Galili, Uri

PY - 2012/9

Y1 - 2012/9

N2 - Aim/Background: To determine the feasibility and safety of intratumoral α-gal glycolipids injection for conversion of human tumors into autologous Tumor Associated Antigens (TAA) vaccine. α-Gal glycolipids bind anti-Gal - the most abundant antibody in humans. Preclinical studies indicated that injected α-gal glycolipids insert into tumor cell membranes, bind anti-Gal and target tumor cells to Antigen Presenting Cells, thereby converting tumors into autologous TAA vaccines. We hypothesized that α-gal glycolipids might have similar utility in humans. Patients and Methods: Eleven patients with advanced solid tumors received one intratumoral injection of 0.1 mg, 1 mg, or 10 mg α-gal glycolipids. The primary endpoint was dose-limiting toxicity (DLT) within 4 weeks. Secondary endpoints included long-term toxicity, autoimmunity, radiological tumor response and survival. Results: There were no DLT and no clinical or laboratory evidence of autoimmunity, or any other toxicity. Few patients had an unexpectedly long survival. Conclusion: Intratumoral injection of α-gal glycolipids is feasible and safe for inducing a protective anti-tumor immune response.

AB - Aim/Background: To determine the feasibility and safety of intratumoral α-gal glycolipids injection for conversion of human tumors into autologous Tumor Associated Antigens (TAA) vaccine. α-Gal glycolipids bind anti-Gal - the most abundant antibody in humans. Preclinical studies indicated that injected α-gal glycolipids insert into tumor cell membranes, bind anti-Gal and target tumor cells to Antigen Presenting Cells, thereby converting tumors into autologous TAA vaccines. We hypothesized that α-gal glycolipids might have similar utility in humans. Patients and Methods: Eleven patients with advanced solid tumors received one intratumoral injection of 0.1 mg, 1 mg, or 10 mg α-gal glycolipids. The primary endpoint was dose-limiting toxicity (DLT) within 4 weeks. Secondary endpoints included long-term toxicity, autoimmunity, radiological tumor response and survival. Results: There were no DLT and no clinical or laboratory evidence of autoimmunity, or any other toxicity. Few patients had an unexpectedly long survival. Conclusion: Intratumoral injection of α-gal glycolipids is feasible and safe for inducing a protective anti-tumor immune response.

KW - α-gal glycolipids

KW - Anti-Gal antibody

KW - Autologous tumor antigens

KW - Cancer immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84867009699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867009699&partnerID=8YFLogxK

M3 - Article

C2 - 22993330

AN - SCOPUS:84867009699

VL - 32

SP - 3861

EP - 3868

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -